Arovella Newsletter December 2023
Welcome to this edition of Arovella’s newsletter. Your Company is progressing well, and I am looking forward to giving you a summary of recent and exciting developments. Since joining as Non-executive Chairman in March 2023, the Company has continued to make significant progress developing its invariant Natural Killer T (iNKT) cell platform and expanded the potential reach of the technology from blood cancers to solid tumours.
Highlights:
Advanced its manufacturing activities through a new partnership with Cell Therapies Pty Ltd in readiness to manufacture ALA-101 for clinical trials in the first half of CY24.
Received positive data demonstrating that the cytokine technology under option from the University of North Carolina can increase the persistence of iNKT cells and enhances their anti-tumour effect in a mouse solid tumour model.
Finalised the closure of its Perth OroMist R&D facility to complete the strategic refocus of the Company towards its iNKT cell platform.
Completed an oversubscribed Placement and SPP to raise a total of $6.3 million.
Progressed its solid tumour strategy by signing an exclusive license with Sparx Group to develop a world-first CAR-iNKT cell therapy targeting a validated target, Claudin 18.2 (CLDN18.2), which is expressed in gastric cancer (GC), gastroesophageal junction cancer (GEJC) and pancreatic Cancer (PC).
Dr Tom Duthy
Chairman
